Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co., Ltd. (Stock code: 688513). The company specializes in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs.
Our products include human APIs, veterinary APIs, mRNA materials and intermediates etc. Qingmu is experienced in exporting API products to more than 40 countries.